G0
G09.F Genomic Vision Société Anonyme
- Market cap
- EUR 693K
- P/E
- -
- P/B
- 4.33x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is G09.F undervalued?
Graham numberThe Graham number of Genomic Vision Société Anonyme cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genomic Vision Société Anonyme fundamental analysis
No fundamental analysis for Genomic Vision Société Anonyme yet.
Genomic Vision Société Anonyme stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision S, an automated scanner that develops life science resear…
Full company profileGenomic Vision Société Anonyme financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genomic Vision Société Anonyme annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.02M | 4.85M | 4.27M | 3.04M | 3.57M | 1.90M | 2.24M | 1.30M | 1.41M | 1.48M | - |
| Gross Profit | 3.94M | 4.80M | 4.17M | 1.87M | 1.92M | 1.37M | 920K | 508K | 807K | 1.27M | - |
| Operating Income | -1.10M | -2.21M | -4.39M | -8.66M | -8.48M | -6.39M | -4.22M | -5.12M | -4.90M | -6.14M | - |
| EBITDA | - | - | - | - | -7.78M | -5.35M | -4.16M | -4.16M | -4.51M | -5.42M | - |
| Net Income | -1.07M | -2.16M | -4.34M | -8.61M | -9.07M | -6.90M | -4.61M | -5.18M | -5.00M | -6.79M | - |
| EPS | - | - | - | - | -1.63 | -0.44 | -0.10 | -0.10 | -0.08 | -0.06 | - |
| Balance Sheet | |||||||||||
| Total Assets | 5.80M | 26.4M | 21.9M | 13.2M | 8.28M | 8.71M | 5.60M | 7.30M | 6.77M | 4.99M | 3.96M |
| Total Liabilities | 4.82M | 3.75M | 3.55M | 3.18M | 4.52M | 4.54M | 2.38M | 4.18M | 3.70M | 6.28M | 6.73M |
| Shareholders' Equity | 982K | 22.7M | 18.4M | 10.0M | 3.76M | 4.17M | 3.23M | 3.12M | 3.07M | -1.29M | -2.77M |
| Cash & Short-term Investments | 3.23M | 22.8M | 15.6M | 6.89M | 2.03M | 3.17M | 1.08M | 1.99M | 2.29M | 760K | 14.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 242K | -3.77M | -5.54M | -8.13M | -7.89M | -5.59M | -5.13M | -3.67M | -4.52M | -4.41M | -5.38M |
| Capital Expenditure | 75.0K | 275K | 1.49M | 542K | 305K | 62.0K | 12.0K | 144K | 99.0K | 102K | 578K |
| Free Cash Flow | - | - | - | - | -8.20M | -5.66M | -5.14M | -3.81M | -4.62M | -4.51M | - |
| Ratios | |||||||||||
| ROE | -108.9% | -9.5% | -23.6% | -85.8% | -241.4% | -165.5% | -142.8% | -165.7% | -162.9% | - | - |
| ROA | -18.4% | -8.2% | -19.8% | -65.2% | -109.6% | -79.2% | -82.3% | -70.9% | -73.8% | -136.1% | - |
| Net Profit Margin | -26.6% | -44.4% | -101.5% | -283.8% | -253.9% | -362.3% | -205.8% | -399.2% | -353.7% | -458.8% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genomic Vision Société Anonyme dividends
Genomic Vision Société Anonyme has not paid dividends in the last 9 fiscal years.
Who owns Genomic Vision Société Anonyme
- Insiders 1.93%
- Institutions 0.00%
- Public & others 98.07%
- Shares outstanding 385M
- Free float 102M
Genomic Vision Société Anonyme company profile
- Company name
- Genomic Vision Société Anonyme
- Ticker
- G09.F
- ISIN
- FR0011799907
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 80 Rue des Meuniers, Bagneux, France, 92220
- Phone
- 33 1 49 08 07 40
- Website
- genomicvision.com
About Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision S, an automated scanner that develops life science research applications of single DNA molecules analysis and delivers fluorescence imaging; FiberSmart, an analysis software for replication combing assays; and accessories, which include combicoverslips, disposable DNA reservoirs, coverslips stickers, and bench holders. It offers FiberProbes; HexaCard, a genomic vision molecular combing technology offering a streamline one-stop-shop solution for biomanufacturing industries; TeloSizer, a novel tool for measurements of physical telomere length that can be applied to various model organisms; and EasyComb, EasyScan, and EasyComb Plus services. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
Genomic Vision Société Anonyme management
6- Mr. Aaron Bensimon Ph.D.Co-Founder, CEO, Chairman of Executive Board & Scientific Director
- Mr. Lionel SeltzAdministrative & Financial Director and Member of the Management Board
- Ms. Emilie ChataignierMember of Executive Board
- Mr. Frederic Hammel MBAChief Operating Officer
- Mr. Mark David LynchGlobal Commercial & Marketing Director
- Ms. Claire FleuryDirector of Human Resources